Liver transplantation is an effective intervention for end-stage liver disease, fulminant hepatic failure, and early hepatocellular carcinoma. Yet, there is marked patient-to-patient variation in liver transplantation outcomes. This calls for novel diagnostics to enable rational deployment of donor livers. Metabolomics is a postgenomic high-throughput systems biology approach to diagnostic innovation in clinical medicine. We report here an original systematic review of the metabolomic studies that have identified putative biomarkers in the context of liver transplantation. Eighteen studies met the inclusion criteria that involved sampling of blood (n = 4), dialysate fluid (n = 4), bile (n = 5), and liver tissue (n = 5). Metabolites of amino acid and nitrogen metabolism, anaerobic glycolysis, lipid breakdown products, and bile acid metabolism were significantly different in transplanted livers with and without graft dysfunction. However, criteria for defining the graft dysfunction varied across studies. This systematic review demonstrates that metabolomics can be deployed in identification of metabolic indicators of graft dysfunction with a view to implicated molecular mechanisms. We conclude the article with a horizon scanning of metabolomics technology in liver transplantation and its future prospects and challenges in research and clinical practice.
Get full access to this article
View all access options for this article.
References
1.
AttiaM, SilvaMA, and MirzaDF. (2008). The marginal liver donor—an update. Transpl Int, 21, 713–724.
2.
BeckonertO, KeunHC, EbbelsTM, et al. (2007). Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc, 2, 2692–2703.
3.
BonneauE, TetreaultN, RobitailleR, BoucherA, and De GuireV. (2016). Metabolomics: Perspectives on potential biomarkers in organ transplantation and immunosuppressant toxicity. Clin Biochem, 49, 377–384.
4.
BruinsmaBG, SridharanGV, WeederPD, et al. (2016). Metabolic profiling during ex vivo machine perfusion of the human liver. Sci Rep, 6, 22415.
5.
ChristiansUMDP, KlawitterJP, and KlawitterJP. (2016). Biomarkers in Transplantation-Proteomics and Metabolomics. Ther Drug Monit 38, Suppl, S70–S74.
6.
ClavienPA, CamargoCA, CroxfordR, LangerB, LevyGA, and GreigPD. (1994). Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg, 220, 109–120.
7.
CortesM, ParejaE, Garcia-CanaverasJC, et al. (2014). Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction. J Hepatol, 61, 564–574.
8.
DuarteIF, StanleyEG, HolmesE, et al. (2005). Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem, 77, 5570–5578.
9.
DunnWB, BaileyNJ, and JohnsonHE. (2005). Measuring the metabolome: Current analytical technologies. Analyst, 130, 606–625.
10.
DunnWB, BroadhurstD, BegleyP, et al. (2011a). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc, 6, 1060–1083.
11.
DunnWB, BroadhurstDI, AthertonHJ, GoodacreR, and GriffinJL. (2011b). Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev, 40, 387–426.
12.
DurandF, RenzJF, AlkoferB, et al. (2008). Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl, 14, 1694–1707.
13.
FaitotF, BeschC, BattiniS, et al. (2018). Impact of real-time metabolomics in liver transplantation: Graft evaluation and donor-recipient matching. J Hepatol, 68, 699–706.
14.
FrancozC, BelghitiJ, and DurandF. (2007). Indications of liver transplantation in patients with complications of cirrhosis. Best Pract Res Clin Gastroenterol, 21, 175–190.
15.
HameedAM, LaurenceJM, LamVWT, PleassHC, and HawthorneWJ. (2017). A systematic review and meta-analysis of cold in situ perfusion and preservation of the hepatic allograft: Working toward a unified approach. Liver Transplant, 23, 1615–1627.
16.
HashimotoK, and MillerC. (2008). The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg, 15, 92–101.
17.
HedayaMS, El MoghazyWM, YasutomoY, et al. (2009). Is biliary bile acid a good predictor for acute cellular rejection in living donor liver transplantation?. Hepatobiliary Pancreat Dis Int, 8, 474–478.
18.
HrydziuszkoO, SilvaMA, PereraMT, et al. (2010). Application of metabolomics to investigate the process of human orthotopic liver transplantation: A proof-of-principle study. OMICS, 14, 143–150.
19.
HrydziuszkoO, ThamaraMTPR, LaingR, et al. (2016). Mass spectrometry based metabolomics comparison of liver grafts from donors after circulatory death (DCD) and Donors after Brain Death (DBD) Used in human orthotopic liver transplantation. PLoS One, 11, e0165884.
20.
LaingRW, MergentalH, and MirzaDF. (2017). Normothermic ex-situ liver preservation: The new gold standard. Curr Opin Organ Transplant, 22, 274–280.
21.
Le DinhH, De RooverA, KabaA, et al. (2012). Donation after cardio-circulatory death liver transplantation. World J Gastroenterol, 18, 4491–4506.
22.
Legido-QuigleyC, McdermottL, Vilca-MelendezH, et al. (2011). Bile UPLC-MS fingerprinting and bile acid fluxes during human liver transplantation. Electrophoresis, 32, 2063–2070.
23.
LumbrerasB, PortaM, MarquezS, PollanM, ParkerLA, and Hernandez-AguadoI. (2008). QUADOMICS: An adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics'-based technologies. Clin Biochem, 41, 1316–1325.
24.
Martin-SanzP, OlmedillaL, DulinE, et al. (2003). Presence of methylated arginine derivatives in orthotopic human liver transplantation: Relevance for liver funchon. Liver Transplant, 9, 40–48.
25.
MathurAK, HeimbachJ, SteffickDE, SonnendayCJ, GoodrichNP, and MerionRM. (2010). Donation after cardiac death liver transplantation: Predictors of outcome. Am J Transplant, 10, 2512–2519.
26.
MckeownDW, BonserRS, KellumJA. (2012). Management of the heartbeating brain-dead organ donor. Br J Anaesth, 108, i96–i107.
27.
MelendezHV, AhmadiD, ParkesHG, RelaM, MurphyG, and HeatonN. (2001). Proton nuclear magnetic resonance analysis of hepatic bile from donors and recipients in human liver transplantation. Transplantation, 72, 855–860.
28.
MoherD, LiberatiA, TetzlaffJ, and AltmanDG. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 6, e1000097.
29.
MonbaliuD, PirenneJ, and TalbotD. (2012). Liver transplantation using donation after cardiac death donors. J Hepatol, 56, 474–485.
30.
NasrallaD, CoussiosCC, MergentalH, et al. (2018). A randomized trial of normothermic preservation in liver transplantation. Nature, 557, 50–56.
31.
OlthoffKM, KulikL, SamsteinB, et al. (2010). Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl, 16, 943–949.
32.
PapaspyridonosK, Garcia-PerezI, AnguloS, et al. (2008). Fingerprinting of human bile during liver transplantation by capillary electrophoresis. J Separation Sci, 31, 3058–3064.
33.
ParkerLA, Gomez SaezN, LumbrerasB, PortaM, and Hernandez-AguadoI. (2010). Methodological deficits in diagnostic research using ‘-omics' technologies: Evaluation of the QUADOMICS tool and quality of recently published studies. PLoS One, 5, e11419.
34.
PattiGJ, YanesO, and SiuzdakG. (2012). Innovation: Metabolomics: The apogee of the omics trilogy. Nat Rev Mol Cell Biol, 13, 263–269.
35.
PereraMT, MirzaDF, and EliasE. (2009). Liver transplantation: Issues for the next 20 years. J Gastroenterol Hepatol 24 Suppl, 3, S124–S131.
36.
PereraMTPR, HigdonR, RichardsDA, et al. (2014). Biomarker differences between cadaveric grafts used in human orthotopic liver transplantation as identified by coulometric electrochemical array detection (CEAD) metabolomics. OMICS, 18, 767–777.
37.
RichardsDA, SilvaMA, MurphyN, WigmoreSJ, and MirzaDF. (2007). Extracellular amino acid levels in the human liver during transplantation: A microdialysis study from donor to recipient. Amino Acids, 33, 429–437.
38.
SerkovaNJ, ZhangY, CoatneyJL, et al. (2007). Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation, 83, 517–521.
39.
SilvaMA, MurphyN, RichardsDA, et al. (2006). Interstitial lactic acidosis in the graft during organ harvest, cold storage, and reperfusion of human liver allografts predicts subsequent ischemia reperfusion injury. Transplantation, 82, 227–233.
40.
SilvaMA, RichardsDA, BramhallSR, AdamsDH, MirzaDF, and MurphyN. (2005). A Study of the Metabolites of Ischemia-Reperfusion Injury and Selected Amino Acids in the Liver Using Microdialysis during Transplantation. Transplantation, 79, 828–835.
41.
SinghHK, YachhaSK, SaxenaR, et al. (2003). A new dimension of 1H-NMR spectroscopy in assessment of liver graft dysfunction. NMR Biomed, 16, 185–188.
42.
StrasbergSM, HowardTK, MolmentiEP, and HertlM. (1994). Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology, 20, 829–838.
43.
TripathiP, LakshmiB, SaxenaR, YachhaSK, RoyR, and KhetrapalCL. (2009). 1H NMR Spectroscopic Study of blood serum for the assessment of liver function in liver transplant patients. J Gastrointestin Liver Dis, 18, 329–336.
44.
Vilca MelendezH, RelaM, SetchellKD, MurphyGM, and HeatonND. (2004). Bile acids analysis: A tool to assess graft function in human liver transplantation. Transpl Int, 17, 286–292.
45.
WhitingP, RutjesAWS, ReitsmaJB, BossuytPMM, and KleijnenJ. (2003). The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25.
46.
WishartDS. (2005). Metabolomics: The principles and potential applications to transplantation. Am J Transplant, 5, 2814–2820.
47.
WishartDS, FeunangYD, MarcuA, et al. (2018). HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res, 46, D608–D617.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
